Feature Paper in Antibiotics for 2019

There has been much speculation about a possible antibiotic Armageddon; this would be the result of having untreatable post-operative infections, and similarly untreatable complications after chemotherapy. The now famous “O’Neill Report” (https://amr-review.org/) suggests that more people could die...

Full description

Saved in:
Bibliographic Details
Sonstige:
Year of Publication:2020
Language:English
Physical Description:1 electronic resource (282 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 04940nam-a2201285z--4500
001 993545835204498
005 20231214133228.0
006 m o d
007 cr|mn|---annan
008 202105s2020 xx |||||o ||| 0|eng d
035 |a (CKB)5400000000044635 
035 |a (oapen)https://directory.doabooks.org/handle/20.500.12854/69089 
035 |a (EXLCZ)995400000000044635 
041 0 |a eng 
100 1 |a Lipman, Jeffrey  |4 edt 
245 1 0 |a Feature Paper in Antibiotics for 2019 
260 |a Basel, Switzerland  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2020 
300 |a 1 electronic resource (282 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
520 |a There has been much speculation about a possible antibiotic Armageddon; this would be the result of having untreatable post-operative infections, and similarly untreatable complications after chemotherapy. The now famous “O’Neill Report” (https://amr-review.org/) suggests that more people could die from resistant bacterial infections by 2050 than from cancer. We are still learning about all the subtle drivers of antibiotic resistance, and realizing that we need a single “whole of health” co-ordinated policy. We ingest what we sometimes feed to animals. There do not seem to be any new classes of antibiotics on our horizon. Perhaps something that has been around “forever” will come to our rescue—bacteriophages! Nevertheless, we have to do things differently, use antibiotics appropriately, for the correct indication, for the correct duration and with the correct dose, and with that, practice good antibiotic stewardship. Whilst by no means comprehensive, this book does cover some of the many topics of antibiotic stewardship. It also addresses some of the older antibiotics, some new combinations, and even some new agents. Last, and by no means least, there are two excellent articles on bacteriophages. 
546 |a English 
650 7 |a Medicine  |2 bicssc 
653 |a Antimicrobial resistance 
653 |a antibiotics 
653 |a antimicrobial stewardship 
653 |a inappropriate prescribing 
653 |a days of therapy 
653 |a Start Smart then Focus 
653 |a piperine 
653 |a piperlongumine 
653 |a antibacterial 
653 |a antifungal 
653 |a synergy 
653 |a non-target feed 
653 |a florfenicol 
653 |a thiamfenicol 
653 |a chloramfenicol 
653 |a HPLC-MS/MS 
653 |a validation 
653 |a swine 
653 |a out-of-hours care 
653 |a primary care 
653 |a quality of care 
653 |a quality indicators 
653 |a practitioners cooperative 
653 |a antibiotic stewardship 
653 |a fluoroquinolones 
653 |a guidelines 
653 |a urinary tract infections 
653 |a quality improvement 
653 |a general practitioners 
653 |a guideline 
653 |a health inequalities 
653 |a health equity assessment tool 
653 |a public health 
653 |a Enterobacteriaceae 
653 |a carbapenem-resistant 
653 |a CRE 
653 |a antibiotic resistance 
653 |a antimicrobials 
653 |a bacteriophages 
653 |a biofilms 
653 |a novel antimicrobials 
653 |a Antibiotics 
653 |a resistance 
653 |a broad-spectrum agents 
653 |a hospital epidemiology 
653 |a antibiotic utilization 
653 |a infection control 
653 |a infection prevention 
653 |a Pseudomonas aeruginosa 
653 |a Acinetobacter baumannii 
653 |a extended-spectrum beta-lactamases 
653 |a carbapenem-resistant Enterobacteriaceae 
653 |a methicillin-resistant Staphylococcus aureus 
653 |a clinical trials 
653 |a infectious disease 
653 |a phage therapy 
653 |a silver complexes 
653 |a camphorimine 
653 |a anti-Candida activity 
653 |a antifungals 
653 |a antibacterials 
653 |a efflux inhibitors 
653 |a efflux pumps 
653 |a erm(41) 
653 |a mutations 
653 |a mycobacteria 
653 |a verapamil 
653 |a actinomycetes 
653 |a bioactivity 
653 |a polyketides 
653 |a polyketide synthases 
653 |a biosynthesis 
653 |a antimicrobial resistance 
653 |a economic evaluation 
653 |a cost-utility analysis 
653 |a cost-effectiveness analysis 
653 |a policy analysis 
653 |a One Health 
653 |a Singapore 
653 |a antibiotic prescribing 
653 |a implementation 
653 |a behavior change 
653 |a stakeholder consultation 
776 |z 3-03943-122-6 
776 |z 3-03943-123-4 
700 1 |a Lipman, Jeffrey  |4 oth 
906 |a BOOK 
ADM |b 2023-12-15 05:47:08 Europe/Vienna  |f system  |c marc21  |a 2022-04-04 09:22:53 Europe/Vienna  |g false 
AVE |i DOAB Directory of Open Access Books  |P DOAB Directory of Open Access Books  |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338103080004498&Force_direct=true  |Z 5338103080004498  |b Available  |8 5338103080004498